GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

Submitted by admin on September 28, 2020 - 10:37am

Source:

Fierce Pharma

News Tags:

GSK

Nucala

hypereosinophilic syndrome

FDA

AstraZeneca

Headline:

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

snippet:

The FDA gave GSK's Nucala the green light to treat hypereosinophilic syndrome (HES), making it the first biologic approved for the disease, the British drugmaker said Friday.

Search form

You are here

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease